CLINICAL_TRIALS
trial_result
· 2016-02-01
Clinical Trial Update: Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer [Phase 2]
Summary
A Phase 2 trial of temozolomide for relapsed sensitive or refractory small cell lung cancer has completed and results were posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-01